Outcomes of prechemotherapy (pCHT) abiraterone (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after androgen deprivation therapy (ADT) + docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a hospital-based registry Journal Article
| Authors: | Francini, E.; Gray, K. P.; Evan, C.; Kaymakcalan, M. D.; Shaw, G. K.; Kantoff, P. W.; Taplin, M. E.; Sweeney, C. |
| Article Title: | Outcomes of prechemotherapy (pCHT) abiraterone (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after androgen deprivation therapy (ADT) + docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a hospital-based registry |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 35 |
| Issue: | 15 Suppl. |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2017-05-20 |
| Language: | English |
| ACCESSION: | WOS:000411931703099 |
| DOI: | 10.1200/JCO.2017.35.15_suppl.e16515 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: e16515 -- Source: Wos |
